BioSpace News Archive

Drug Development

New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced results from the pivotal Phase 3 Risperidone Subcutaneous Extended-release study comparing TV-46000/mdc-IRM once monthly and TV-46000/mdc-IRM once every two months with placebo in patients with schizophrenia who underwent stabilization on oral risperidone.

October 30, 2021
·
9 min read
Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY” for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.

October 30, 2021
·
5 min read